Oyster Point Pharma
Oyster Point Pharma, Inc. is an American biopharmaceutical based in Princeton, New Jersey, focusing on the development of pharmaceutical therapies to treat ophthalmic diseases.[2]
| Type | Public company |
|---|---|
| Nasdaq: OYST | |
| Industry | Biotechnology |
| Founded | 2015[1] |
| Headquarters | , |
Key people | Jeffrey Nau (President and CEO) |
| Website | www |
Products
The lead product of the company is Tyrvaya. In October 2021, it was the first nasal spray approved by Food and Drug Administration to treat dry eye syndrome.[3]
Initial public offering and stock history
Prior to going public, Oyster Point Pharma operated at a loss of $16.5 million in 2018.[4] In February 2019, still at clinical stage, the company raised $93 million in its Series B funding round.[5][6]
In October 2019, the company issued 5-million shares in the initial public offering with NASDAQ Global Select Market at the price of $16 per share with the first trading day on October 31.[7]
References
- "SEC FORM S-1". Oyster Point Pharma. Retrieved 27 April 2022.
- "Oyster Point Pharma Inc". Reuters. Retrieved 27 April 2022.
- Harrison, Laird (27 October 2021). "FDA Approves First Nasal Spray for Dry Eye". WenMD Health News. Retrieved 27 April 2022.
- Marinova, Polina (31 October 2019). "Fair's CEO Scott Painter Resigns as Car-Leasing Startup Seeks a Path to Profitability". Fortune. Retrieved 27 April 2022.
- Marinova, Polina (26 February 2019). "Term Sheet — Tuesday, February 26". Fortune. Retrieved 27 April 2022.
- Gormley, Brian (26 February 2019). "Oyster Point Pharma Banks $93 Million for Dry Eye Therapy". Wall Street Journal Pro. Retrieved 27 April 2022.
- Vecchione, Anthony (31 October 2019). "Oyster Point Pharma shares gain in IPO". NJBIZ. Retrieved 27 April 2022.
External links
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.